文献速递肿瘤 PET/CT甲状腺核医学核素与放射性配体治疗

疫苗相关淋巴结:COVID-19疫苗接种时代18F-氟胆碱与68Ga-PSMA-11 PET/CT的新兴陷阱

Vaccine-Related Lymph Nodes: The Emerging Pitfalls of 18F-Fluorocholine and 68Ga-PSMA-11 PET/CT in the Era of COVID-19 Vaccination.
PubMed 文献 · Clin Nucl Med · 2022-04-27

本研究评估COVID-19疫苗接种后,使用非18F-FDG放射性药物进行PET/CT时疫苗相关淋巴结的发生率及特征。226例连续患者中,18F-氟胆碱PET/CT阳性率为42.5%(51/120),68Ga-PSMA-11为12.7%(10/79),18F-FDOPA和68Ga-DOTATOC未见疫苗相关淋巴结。疫苗相关淋巴结与放射性药物种类、接种剂次、接种与PET/CT间隔短及前列腺癌患者PSA水平较高相关。

要点

  • COVID-19疫苗接种后,18F-氟胆碱PET/CT疫苗相关腋窝及锁骨上淋巴结阳性率为42.5%(51/120)。
  • 68Ga-PSMA-11 PET/CT疫苗相关淋巴结阳性率为12.7%(10/79),18F-FDOPA和68Ga-DOTATOC未见。
  • 85%的疫苗相关淋巴结出现在注射后30天内,大小和摄取有限,多局限于腋窝1区。

核心结论

  • COVID-19疫苗接种后检出阳性淋巴结并非18F-FDG PET/CT独有模式,在18F-氟胆碱PET/CT上常见,在68Ga-PSMA-11 PET/CT上可能出现。
  • 在当前疫情背景下,将PET/CT表现与临床数据(如注射日期和部位)结合似乎至关重要,正如前列腺癌所用放射性药物一样,以避免PET/CT误判和不正确的患者治疗。
  • 对于18F-FDOPA或68Ga-DOTATOC PET/CT,这种影响似乎较小。

研究设计与样本

  • 2021年2月至7月连续纳入至少接种1剂COVID-19疫苗且因任何适应症接受非18F-FDG全身PET/CT的患者,共226例。
  • 120例接受18F-氟胆碱PET/CT,79例接受68Ga-PSMA-11 PET/CT,6例接受18F-FDOPA PET/CT,21例接受68Ga-DOTATOC PET/CT。
  • 对前列腺癌患者进行统计分析以确定与疫苗相关淋巴结检出相关的交互因素。

主要发现

  • 18F-氟胆碱PET/CT疫苗相关腋窝及锁骨上淋巴结阳性率为42.5%(51/120),68Ga-PSMA-11为12.7%(10/79)。
  • 18F-FDOPA或68Ga-DOTATOC PET/CT患者均未出现疫苗相关淋巴结肿大。
  • 疫苗相关淋巴结与放射性药物种类(P < 10-4)、接种剂次(P = 0.041)、接种与PET/CT间隔短(P < 10-5)及前列腺癌患者较高PSA水平(P = 0.032)相关,与年龄或疫苗类型无关。
  • 85%的疫苗相关淋巴结出现在注射后30天内,大小和摄取有限,多局限于腋窝1区。
  • 67.3%(152/226)接种BNT162b2mRNA(Pfizer-BioNTech),26.5%(60/226)接种ChAdOx1-S(AstraZeneca),4.9%(11/226)接种mRNA-1273(Moderna),1.3%(3/226)接种Ad26.COV2.S(Janssen)。

临床怎么用

  • 作者认为,在当前疫情背景下,将PET/CT表现与临床数据(如注射日期和部位)结合似乎至关重要,以避免PET/CT误判和不正确的患者治疗。
  • 作者认为,对于18F-FDOPA或68Ga-DOTATOC PET/CT,疫苗相关淋巴结的影响似乎较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Vaccination against coronavirus disease 2019 (COVID-19) is currently under worldwide deployment. The consequences of this vaccination can be seen in radiology and nuclear medicine explorations with visualization of axillary lymph nodes (LNs), as observed on ultrasonography, MRI, or 18F-FDG PET/CT.We aimed to evaluate on PET/CT the incidence of vaccine-related LNs and their characteristics after COVID-19 vaccination, using several radiopharmaceuticals different from 18F-FDG. PATIENTS AND METHODS: Between February and July 2021, all consecutive patients undergoing a whole-body PET/CT for any indication using a different radiopharmaceutical from 18F-FDG were eligible for inclusion if they had received at least 1 dose of the COVID-19 vaccine. The radiopharmaceutical administered and vaccine type were recorded for each patient. The incidence of positive vaccine-related axillary and supraclavicular LNs on PET/CT was our primary finding, along with the nodes characteristics. Statistical analyses were performed for patients with prostate cancer (PCa) to determine certain interaction factors that were associated with the detection of vaccine-related LNs. RESULTS: Of the 226 patients in our cohort study, 120 patients underwent an 18F-fluorocholine PET/CT, 79 a 68Ga-PSMA-11 PET/CT, 6 an 18F-FDOPA PET/CT, and 21 a 68Ga-DOTATOC PET/CT. A total of 67.3% of patients (152/226) received BNT162b2mRNA (Pfizer-BioNTech), 26.5% (60/226) ChAdOx1-S (AstraZeneca), 4.9% (11/226) mRNA-1273 (Moderna), and 1.3% (3/226) Ad26.COV2.S (Janssen). The incidence of positive vaccine-related axillary and supraclavicular LNs was 42.5% (51/120 patients) on PET/CT using 18F-fluorocholine and 12.7% (10/79 patients) with 68Ga-PSMA-11. None of our patients undergoing 18F-FDOPA or 68Ga-DOTATOC PET/CT presented any vaccine-related lymphadenopathy. Vaccine-related LNs were statistically associated with the nature of the radiopharmaceutical (P < 10-4), with the number of vaccine doses received (P = 0.041), with a short delay between vaccination and PET/CT realization (P < 10-5), and with a higher prostate-specific antigen level for patients with PCa (P = 0.032), but not with age or vaccine type. The vaccine-related nodes appeared in 85% of the cases, in the 30 days after vaccine injection, were limited in size and uptake, and were most often limited to the axilla level 1 area. CONCLUSIONS: Detecting positive LNs after COVID-19 vaccination is not an exclusive 18F-FDG PET/CT pattern but is common on 18F-fluorocholine and possible on 68Ga-PSMA-11 PET/CT. Confronting PET/CT findings with clinical data (such as date and site of injection) seems essential in the current pandemic context, just as it does for the radiopharmaceuticals used in PCa to avoid PET/CT misinterpretation and incorrect patient treatment. For 18F-FDOPA or 68Ga-DOTATOC PET/CT, this seems to have a lesser impact.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ah-Thiane L, Ferrer L, Maucherat B, et al. Vaccine-Related Lymph Nodes: The Emerging Pitfalls of 18F-Fluorocholine and 68Ga-PSMA-11 PET/CT in the Era of COVID-19 Vaccination. Clin Nucl Med. 2022. PMID: 35675134. doi:10.1097/RLU.0000000000004190

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。